Identificazione della malattia residua minima nel midollo e nel sangue periferico nel neuroblastoma. Implicazioni prognostiche e terapeutiche.
Lawrence Faulkner(Faulkner University), Bruno De Bernardi(Istituto Giannina Gaslini), de Medicina(Florence (Netherlands)), Maria Valeria Corrias(Boston Children's Hospital), A. Tamburini, Claudia Milanaccio(Istituto Giannina Gaslini), Antonella Paoli, Veronica Tintori, Alberto Garaventa(Istituto Giannina Gaslini), Paola Scaruffi(Azienda Ospedaliera S.Maria), Elisabetta Viscardi(Azienda Ospedale - Università Padova), Gabriella Bernini(University of Florence), M. S. Lo Piccolo(Palmetto Hematology Oncology), Annalisa Tondo, Massimo Brisigotti, Cristina Rosanda(Palmetto Hematology Oncology)
Unknown
May 1, 1998
Cited by 0
Related Papers
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
|Journal of Clinical Oncology|1993|2.3k
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.
|Journal of Clinical Oncology|1988|608
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study
|The Lancet Oncology|2009|196
Impact of infertility and infertility treatments on quality of life and levels of anxiety and depression in women undergoing <i>in vitro</i> fertilization
|Gynecological Endocrinology|2019|188
Mitochondrial DNA content in embryo culture medium is significantly associated with human embryo fragmentation
|Human Reproduction|2013|172